Sumitomo Pharma (4506.T) Earnings Analysis
Sumitomo Pharma (4506.T) next reports earnings on 2026-07-31. Last quarter (2026-01-30) it beat with EPS 22.19 JPY vs -0.8704 JPY est (+2649.4%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E 4.78.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 4506.T next report earnings?
| Next earnings date | 2026-07-31 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | 114.10B |
4506.T earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-01-30 | 22.19 JPY | -0.8704 JPY | +2649.4% | Beat |
| 2025-05-12 | 6.08 JPY | -12.32 JPY | +149.4% | Beat |
| 2025-01-31 | 134.53 JPY | -2.52 JPY | +5438.5% | Beat |
| 2024-10-30 | -121.23 JPY | 15 JPY | -908.2% | Miss |
| 2024-07-31 | 40.11 JPY | -2.52 JPY | +1691.7% | Beat |
Beat rate: 4/5 (80%) over reported quarters with consensus data.
4506.T valuation and analyst view
| Trailing P/E | 4.78 |
|---|---|
| Trailing EPS | 268.98 JPY |
| Price / book | 1.75 |
| Dividend yield | 0.00% |
| Market cap | 576.89B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Sumitomo Pharma (4506.T)'s next earnings date?
Sumitomo Pharma is next scheduled to report on 2026-07-31 and revenue estimate of 114.10B.
Did 4506.T beat earnings last quarter?
In its 2026-01-30 report, 4506.T posted EPS of 22.19 JPY versus a -0.8704 JPY estimate — a beat of 2649.4%.
What is 4506.T's earnings track record?
Over the last 5 reported quarters with consensus data, 4506.T beat estimates 4 times (80%).
What is 4506.T's current P/E ratio and EPS?
4506.T trades at a trailing P/E of 4.78 on trailing EPS of 268.9787792065925 JPY.
What do analysts rate 4506.T?
4506.T has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.